Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined with Capecitabine and Oxaliplatin in First-line Treatment of Patients with PD-L1-negative Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined with Capecitabine and Oxaliplatin in First-line Treatment of Patients with PD-L1-negative Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depoxythilone (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Beijing Biostar Technologies

Most Recent Events

  • 15 Sep 2025 Status changed to recruiting.
  • 15 Sep 2025 According to Beijing Biostar Pharmaceuticals media release, the first patients have been dosed for the phase II/III for first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma on 11 Sep 2025 .
  • 27 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top